GlaxoSmithKline Retained Earnings

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC retained earnings fundamental analysis lookup allows you to check this and other indicators for GlaxoSmithKline PLC or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Retained Earnings

 
Refresh
GlaxoSmithKline PLC Accumulated Retained Earnings Deficit are decreasing as compared to previous years. The last year's value of Accumulated Retained Earnings Deficit was reported at 4.53 Billion. The current Price to Earnings Ratio is estimated to increase to 25.29, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are estimated to decrease to under 6 B.

GlaxoSmithKline Retained Earnings Analysis

Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Retained Earnings 
 = 
Beginning RE + Income 
Dividends 
More About Retained Earnings | All Equity Analysis

Current GlaxoSmithKline PLC Retained Earnings

4.89 B

GlaxoSmithKline Retained Earnings Over Time Pattern

 GlaxoSmithKline PLC Accumulated Retained Earnings Deficit 
      Timeline 

About Retained Earnings

Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Compare to competition

GlaxoSmithKline PLC Retained Earnings Related Assessment

  Accumulated Retained Earnings Deficit

Based on the latest financial disclosure GlaxoSmithKline PLC has Retained Earnings of 4.89 B. This is 424.78% higher than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Retained Earnings for all stocks is 47.61% higher than the company.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

GlaxoSmithKline PLCCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee234.94 K236.26 K280.09 K306.57 K322.77 K339.45 K297.49 K
Average Assets41.37 B47.05 B56.26 B57.73 B57.22 B68.88 B64.51 B
Earnings before Tax2.89 B10.58 B1.79 B2.89 B4.38 B5.6 B5.21 B
Average Equity5.63 B4.69 B3.12 B528 M1.86 B7.59 B6.44 B
Enterprise Value135.45 B130.34 B118.87 B112.37 B121.13 B155.97 B157.75 B
Free Cash Flow5.13 B3.32 B6.66 B6.99 B8.57 B8.36 B8.31 B
Invested Capital29.76 B29 B29.23 B19.77 B34.77 B39.93 B37.66 B
Tangible Asset Value28.61 B31.61 B34.34 B33.09 B35.08 B38.17 B38.38 B
Working Capital1.38 B3.17 B(2.29 B)(10.66 B)(5.56 B)(4.56 B)(4.68 B)
Interest Coverage5.2816.123.495.68136.42146.89158.48
Calculated Tax Rate4.6620.4945.3538.6115.8115.523.02
PPandE Turnover2.572.562.722.792.813.153.33
Receivables Turnover4.734.995.085.325.255.214.85
Inventory Turnover2.181.81.981.891.941.862.08
Operating Margin14.2941.777.8912.3616.8219.5822.25
Return on Investment13.6144.6210.5620.221.8518.2823.2
Cash Flow Per Share1.060.531.321.41.71.611.37
Revenue to Assets0.570.450.470.540.530.420.55
Quick Ratio0.660.830.560.360.450.480.63
Asset Turnover0.630.560.510.50.520.540.49
Book Value per Share1.61.910.42(0.025)1.414.244.57
Current Ratio1.11.240.880.60.750.810.86
Debt to Equity Ratio8.388.7248.15(777.82)14.395.385.8
Dividend Yield0.0620.0610.0720.0580.0560.0430.0541
EBITDA Margin0.160.470.0910.120.170.190.2

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page